Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Promote ABL Products for Next-generation Sequencing

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories said today it signed a non-exclusive agreement with Roche Diagnostics for the promotion of certain ABL products.

In particular, the deal is aimed at promoting ABL's next-generation sequencing platform called DeepChek with Roche's NGS systems, the 454 GS Junior and 454 GS FLX+, for molecular virology. The deal covers Europe, the Middle East, Africa, and Latin America.

DeepChek is a solution for managing and analyzing NGS data.

The principal goals of the deal are to "provide our mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity, and meaningful genotyping, and drug resistance reporting for personalized healthcare," ABL said.

Financial and other terms were not disclosed.

ABL is a Luxembourg-based developer of informatics tools for personalized medicine. In June it acquired all the assets of Evivar Medical.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.